v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Series C Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Subscription Receivable
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Total
Balance at the beginning at Dec. 31, 2024 $ 15,507              
Balance at the beginning (in shares) at Dec. 31, 2024 973,000              
Increase (Decrease) in Temporary Equity Deficit                
Series C convertible preferred stock conversion (in shares) (155,000)              
Series C convertible preferred stock conversion $ (2,107)              
Balance at the end at Sep. 30, 2025 $ 13,400              
Balance at the end (in shares) at Sep. 30, 2025 818,000              
Balance at the beginning at Dec. 31, 2024   $ 1,328 $ 1,344,720   $ (79) $ (1,443,499) $ 3,043 $ (94,487)
Balance at the beginning (in shares) at Dec. 31, 2024   1,328,622,000            
Increase (Decrease) in Stockholders' Deficit                
Series C convertible preferred stock conversion   $ 5 2,102         2,107
Series C convertible preferred stock conversion (in shares)   3,866,000            
Issuance of common stock for cash, net   $ 78 17,226         17,304
Issuance of common stock for cash, net (in shares)   78,523,000            
Warrants exercised for cash     23         23
Warrants exercised for cash (in shares)   104,000            
Issuance of common stock for conversion of debt and accrued interest   $ 107 27,626         27,733
Issuance of common stock for conversion of debt and accrued interest (in shares)   107,034,000            
Stock-based compensation     1,022         1,022
Stock-based compensation (in shares)   150,000            
Reclassification of liability classified warrants to equity     3,460         3,460
Warrant modifications     1,178         1,178
Deemed dividend related to warrant modifications     (1,178)         (1,178)
Net loss           (61,550)   (61,550)
Cumulative translation adjustment             (4,260) (4,260)
Balance at the end at Sep. 30, 2025   $ 1,518 1,396,179   (79) (1,505,049) (1,217) (108,648)
Balance at the end (in shares) at Sep. 30, 2025   1,518,299,000            
Balance at the beginning at Jun. 30, 2025 $ 13,753              
Balance at the beginning (in shares) at Jun. 30, 2025 842,000              
Increase (Decrease) in Temporary Equity Deficit                
Series C convertible preferred stock conversion (in shares) (24,000)              
Series C convertible preferred stock conversion $ (353)              
Balance at the end at Sep. 30, 2025 $ 13,400              
Balance at the end (in shares) at Sep. 30, 2025 818,000              
Balance at the beginning at Jun. 30, 2025   $ 1,459 1,378,300   (79) (1,478,220) (1,849) (100,389)
Balance at the beginning (in shares) at Jun. 30, 2025   1,458,761,000            
Increase (Decrease) in Stockholders' Deficit                
Series C convertible preferred stock conversion   $ 1 352         353
Series C convertible preferred stock conversion (in shares)   603,000            
Issuance of common stock for cash, net   $ 22 4,840         4,862
Issuance of common stock for cash, net (in shares)   22,385,000            
Issuance of common stock for conversion of debt and accrued interest   $ 36 8,954         8,990
Issuance of common stock for conversion of debt and accrued interest (in shares)   36,550,000            
Stock-based compensation     273         273
Reclassification of liability classified warrants to equity     3,460         3,460
Warrant modifications     353         353
Deemed dividend related to warrant modifications     (353)         (353)
Net loss           (26,829)   (26,829)
Cumulative translation adjustment             632 632
Balance at the end at Sep. 30, 2025   $ 1,518 1,396,179   (79) (1,505,049) (1,217) (108,648)
Balance at the end (in shares) at Sep. 30, 2025   1,518,299,000            
Balance at the beginning at Dec. 31, 2025 $ 12,710              
Balance at the beginning (in shares) at Dec. 31, 2025 784,347              
Increase (Decrease) in Temporary Equity Deficit                
Series C convertible preferred stock conversion (in shares) (146,000)              
Series C convertible preferred stock conversion $ (2,312)              
Balance at the end at Sep. 30, 2026 $ 10,398              
Balance at the end (in shares) at Sep. 30, 2026 637,614              
Balance at the beginning at Dec. 31, 2025   $ 1,567 1,442,830 $ (12) (79) (1,503,661) (925) $ (60,280)
Balance at the beginning (in shares) at Dec. 31, 2025   1,567,433,000            
Balance at the beginning (in shares) at Dec. 31, 2025       (12,000,000)       12,000,000
Increase (Decrease) in Stockholders' Deficit                
Series C convertible preferred stock conversion   $ 4 2,308         $ 2,312
Series C convertible preferred stock conversion (in shares)   3,668,000            
Issuance of common stock for cash, net   $ 13 2,991         3,004
Issuance of common stock for cash, net (in shares)   12,926,000            
Warrants exercised for cash     28         28
Warrants exercised for cash (in shares)   107,000            
Cashless warrant exercise (in shares)   140,000            
Issuance of common stock for conversion of debt and accrued interest   $ 189 36,734         36,923
Issuance of common stock for conversion of debt and accrued interest (in shares)   189,008,000            
Issuance of common stock as debt offering cost   $ 1 149         150
Issuance of common stock as debt offering cost (in shares)   833,000            
Issuance of warrants in conjunction with convertible note at fair value     776         776
Stock-based compensation     617         617
Warrant modifications     912         912
Deemed dividend related to warrant modifications     (910)         (910)
Net loss           (41,052)   (41,052)
Cumulative translation adjustment             818 818
Balance at the end at Sep. 30, 2026   $ 1,774 1,486,435 $ (12) (79) (1,544,713) (107) $ (56,702)
Balance at the end (in shares) at Sep. 30, 2026   1,774,115,000            
Balance at the end (in shares) at Sep. 30, 2026       (12,000,000)       12,000,000
Balance at the beginning at Jun. 30, 2026 $ 10,398              
Balance at the beginning (in shares) at Jun. 30, 2026 638,000              
Balance at the end at Sep. 30, 2026 $ 10,398              
Balance at the end (in shares) at Sep. 30, 2026 637,614              
Balance at the beginning at Jun. 30, 2026   $ 1,681 1,469,433 $ (12) (79) (1,515,951) (246) $ (45,174)
Balance at the beginning (in shares) at Jun. 30, 2026   1,681,338,000            
Balance at the beginning (in shares) at Jun. 30, 2026       (12,000,000)        
Increase (Decrease) in Stockholders' Deficit                
Warrants exercised for cash     8         8
Warrants exercised for cash (in shares)   28,000            
Issuance of common stock for conversion of debt and accrued interest   $ 93 16,070         16,163
Issuance of common stock for conversion of debt and accrued interest (in shares)   92,749,000            
Issuance of warrants in conjunction with convertible note at fair value     776         776
Stock-based compensation     148         148
Warrant modifications     248         248
Deemed dividend related to warrant modifications     (248)         (248)
Net loss           (28,762)   (28,762)
Cumulative translation adjustment             139 139
Balance at the end at Sep. 30, 2026   $ 1,774 $ 1,486,435 $ (12) $ (79) $ (1,544,713) $ (107) $ (56,702)
Balance at the end (in shares) at Sep. 30, 2026   1,774,115,000            
Balance at the end (in shares) at Sep. 30, 2026       (12,000,000)       12,000,000